Genmab falls after small cancer drug sales miss, lack of outlook hike

Genmab A/S

06/11/2026 08:30

** Shares in Genmab GMAB.CO fall around 4% after the Danish drugmaker posted Q3 results, with a slight miss on a cancer drug EPKINLY sales, and lack of FY guidance hike
** Genmab's cancer drug EPKINLY global sales rose to $491 million in the first nine months, a 47% increase, but slightly below Jyske Bank estimates, the broker says
** The broker sees Genmab's maintained FY guidance of revenue at $4.3 billion to $4.5 billion and adjusted earnings of $1.1 billion to $1.4 billion as a "small disappointment"
** It calls the quarterly results "undramatic", saying it does not take much to pressure shares after a sharp share price rise in October
** Including the session's drop, shares are up around 72% YTD


 (Reporting by Vera Dvorakova)
 ((vera.dvorakova@thomsonreuters.com))